Structure Therapeutics Inc.
corporate_fare Company Profile
Structure Therapeutics Inc. (NASDAQ:GPCR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for GPCR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-11, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for GPCR spans 10-Q, 8-K, 424B5, 10-K.
Recent high-impact activity:
- Structure Therapeutics Posts $1.98/Share Q3 Loss, Nearly Triple the 58-Cent Consensus
- Structure Therapeutics Q3 2026: Net Loss Widens to $144.8M, $1.2B Cash Through 2028
- Structure Therapeutics Q3 2026: Net Loss Widens to $144.8M, $1.2B Cash Through 2028
- Aleniglipron Shows 16.2% Weight Loss at 72 Weeks, CEO Touts Safety and Cost Edge
- Positive Phase 1/2a and 72-Week OLE Data Reported Across Oral Amylin and GLP-1 Programs
Financial Snapshot
Short Interest & Short Volume
6.50 days to coverFINRA reported short interest of 5,927,622 shares in GPCR as of the October 30, 2026 settlement, a 17.1% decrease from the prior period — about 6.5 days to cover at its recent average daily volume. On November 19, 2026, 40.7% of GPCR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.